Synthesis of cysteinylphenol, cysteaminylphenol, and related compounds, and in vivo evaluation of antimelanoma effect

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Archives of Dermatological Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF00417318PMID 3674957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modification of dopa toxicity in human tumour cells.

  1985cited by this paper
• In vitro studies of 2,4-dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells.

  1985cited by this paper
• Antihypertensive activities of phenyl aminoethyl sulfides, a class of synthetic substrates for dopamine beta-hydroxylase.

  1984cited by this paper
• Characterization of melanogenesis and morphogenesis of melanosomes by physicochemical properties of melanin and melanosomes in malignant melanoma.

  1984cited by this paper
• Unique location of melanoma, types of chemotherapy and immunotherapy, and survival of melanoma patients in Japan

  1984cited by this paper
• Therapeutic effect of dopamine infusion on human malignant melanoma.

  1982cited by this paper
• Therapeutic effect of dopamine infusion on human malignant melanoma.

  1982cited by this paper
• Synthesis and antitumor activity of cysteinyl-3,4-dihydroxyphenylalanines and related compounds.

  1981cited by this paper
• STRUCTURAL ANALOGS OF L-GLUTAMIC ACID Γ-(4-HYDROXYANILIDE) AND Γ-(3,4-DIHYDROXYANILIDE) AS POTENTIAL AGENTS AGAINST MELANOMA

  1980cited by this paper
• Selective toxicity of 5-S-cysteinyldopa, a melanin precursor, to tumor cells in vitro and in vivo.

  1980cited by this paper
• Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma.

  1980cited by this paper
• Survival of mice receiving melanoma transplants is promoted by hydroquinone.

  1980cited by this paper
• Melanocytotoxicity and the mechanism of activation of gamma-L-glutaminyl-4-hydroxybenzene.

  1980cited by this paper
• Melanocytotoxicity and the Mechanism of Activation of γ-L-Glutaminyl-4-hydroxybenzene

  1980cited by this paper
• An experimental approach to the chemotherapy of melanoma.

  1980cited by this paper
• 3,4-Dihydroxybenzylamine: a dopamine analog with enhanced antitumor activity against B16 melanoma.

  1979cited by this paper
• Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.

  1979cited by this paper
• The cytotoxicity of gamma-L-glutaminyl-4-hydroxybenzene for cells that contain tyrosinase, a study of melanocytes in the hair follicle of the mouse.

  1979cited by this paper
• DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine.

  1979cited by this paper
• Structural analogues of L-glutamic Acid gamma-(4-hydroxyanilide) and gamma-(3,4-dihydroxyanilde) as potential agents against melanoma.

  1979cited by this paper
• The toxicity of melanin precursors.

  1978cited by this paper
• Enhancement of L-dopa incorporation into melanoma by dopa decarboxylase inhibition.

  1978cited by this paper
• DTIC (NSC-45388) in malignant melanoma: a perspective.

  1976cited by this paper
• Factors regulating growth and pigmentation of melanoma cells.

  1976cited by this paper
• DTIC (NSC-45388) in malignant melanoma: a perspective.

  1976cited by this paper
• Tyrosinase-mediated inhibition of in vitro leucine incorporation into mouse melanoma by 4-isopropylcatechol.

  1975cited by this paper
• Mechanism of depigmentation by hydroquinone.

  1974cited by this paper
• PROTOCOLS FOR SCREENING CHEMICAL AGENTS AND NATURAL PRODUCTS AGAINST ANIMAL TUMORS AND OTHER BIOLOGICAL SYSTEMS

  1972cited by this paper
• Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

  1966cited by this paper
• Studies on Eczematous Sensitizations: The Specificity of the Sensitization from the Point of View of Chemical Configuration

  1945cited by this paper

• A Sulfur Containing Melanogenesis Substrate, N-Pr-4-S-CAP as a Potential Source for Selective Chemoimmunotherapy of Malignant Melanoma

  2023cites this paper
• A Review on the Antimutagenic and Anticancer Effects of Cysteamine

  2023cites this paper
• Immunomodulation of Melanoma by Chemo-Thermo-Immunotherapy Using Conjugates of Melanogenesis Substrate NPrCAP and Magnetite Nanoparticles: A Review

  2022cites this paper
• Molecular Events in the Melanogenesis Cascade as Novel Melanoma-Targeted Small Molecules: Principle and Development

  2022cites this paper
• A cell-based evaluation of human tyrosinase-mediated metabolic activation of leukoderma-inducing phenolic compounds.

  2022cites this paper
• Remembering Keisuke Fujita, M.D., Ph.D., President and Founder of Fujita Health University, and his contributions to medical science and education

  2021cites this paper
• The Melding of Drug Screening Platforms for Melanoma

  2019cites this paper
• RADIOCHEMOTHERAPY USNG PHENOLC THOETERAMINES AND ACYL

  2017cites this paper
• Unnatural Amino Acid Synthesis by Thermostable O-Phospho-l-serine Sulfhydrylase from Hyperthermophilic Archaeon Aeropyrum pernix K1

  2017cites this paper
• Development of radioiodine-labeled 4-hydroxyphenylcysteamine for specific diagnosis of malignant melanoma.

  2015influential citation
• Three-dimensional magnetic cell array for evaluation of anti-proliferative effects of chemo-thermo treatment on cancer spheroids

  2015cites this paper
• N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.

  2012cites this paper
• Melanoma‐targeted chemo‐thermo‐immuno (CTI)‐therapy using N‐propionyl‐4‐S‐cysteaminylphenol‐magnetite nanoparticles elicits CTL response via heat shock protein‐peptide complex release

  2010cites this paper
• Indirect oxidation of the antitumor agent procarbazine by tyrosinase--possible application in designing anti-melanoma prodrugs.

  2008cites this paper
• 4‐S‐Cysteaminylphenol‐loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma

  2007cites this paper
• Small compounds for 'targeted radiotherapy

  2007influential citation
• Selective Cytotoxicity of 4-5'-Cysteaminylphenol on Follicular Melanocytes of the Black Mouse: Rational Basis for Its Application to Melanoma Chemotherapy1

  2006cites this paper
• In vivo antimelanoma effects of 4-S-cysteaminylphenol, a newly synthesized therapeutic agent specific to melanoma

  2005cites this paper
• Thymidylate synthase as a target enzyme for the melanoma-specific toxicity of 4-S-cysteaminylphenol andN-acetyl-4-S-cysteaminylphenol

  2004cites this paper
• A novel radiopharmaceutical for detection of malignant melanoma, based on melanin formation: 3-iodo-4-hydroxyphenyl-L-cysteine

  2003cites this paper
• Comparison of in vitro cytotoxicity of N‐acetyl and N‐propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity

  2000cites this paper
• Synthesis and antimelanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol.

  2000cites this paper
• Sulfur containing tyrosine analogs can cause selective melanocytotoxicity involving tyrosinase-mediated apoptosis.

  1999cites this paper
• Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs.

  1999cites this paper
• The in vivo melanocytotoxicity and depigmenting potency of N‐2,4‐acetoxyphenyl thioethyl acetamide in the skin and hair

  1995cites this paper
• Antimelanoma effect of 4-S-cysteaminylcatechol, an activated form of 4-S-cysteaminylphenol.

  1995cites this paper
• Development of an in vitro primary screen for skin depigmentation and antimelanoma agents.

  1994cites this paper
• The synthesis of N-acetyl-4-S-cysteaminyl [U-14C]phenol as a basis for the development of an antimelanoma and melanoma-radioimaging agent.

  1994cites this paper
• Effects of tyrosinase activity on the cytotoxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol in melanoma cells.

  1992cites this paper
• Selective cytotoxicity of N‐acetyl‐4‐S‐cysteaminylphenol on follicular melanocytes of black mice

  1991cites this paper
• N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma.

  1991cites this paper
• The killing effect of 4-S-cysteaminylphenol, a newly synthesised melanin precursor, on B16 melanoma cell lines.

  1991cites this paper
• Tyrosine transport in a human melanoma cell line as a basis for selective transport of cytotoxic analogues.

  1991cites this paper
• The in vivo antimelanoma effect of 4‐S‐cysteaminylphenol and its N‐acetyl derivative

  1990cites this paper
• Mechanism of growth inhibition of melanoma cells by 4-S-cysteaminylphenol and its analogues.

  1990cites this paper
• 4-S-cysteaminylphenol and its analogues as substrates for tyrosinase and monoamine oxidase.

  1990cites this paper
• Melanocytotoxicity and antimelanoma effects of phenolic amine compounds in mice in vivo.

  1990cites this paper
• Selective cytotoxicity of a phenolic melanin precursor, 4-S-cysteaminylphenol, on in vitro melanoma cells.

  1989cites this paper
• Phenolic melanin precursors provide a rational approach to the design of antitumor agents for melanoma.

  1989cites this paper
• The synthesis of 4-S-cysteinyl-[U-14C]phenol, an experimental antimelanoma agent.

  1989cites this paper